Journal article
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Abstract
Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and increased survival in xenograft models. Methods We conducted a Phase I study of idasanutlin (microprecipitate bulk powder formulation) to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, food effect, and clinical activity in patients with advanced malignancies. Schedules …
Authors
Italiano A; Miller WH; Blay J-Y; Gietema JA; Bang Y-J; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL
Journal
Investigational New Drugs, Vol. 39, No. 6, pp. 1587–1597
Publisher
Springer Nature
Publication Date
12 2021
DOI
10.1007/s10637-021-01141-2
ISSN
0167-6997